{
    "Trade/Device Name(s)": [
        "VITROS Immunodiagnostic Products CA 19-9TM Reagent Pack",
        "VITROS CA19-9 Assay"
    ],
    "Submitter Information": "Ortho-Clinical Diagnostics Inc.",
    "510(k) Number": "K231525",
    "Predicate Device Reference 510(k) Number(s)": [
        "K052889"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NIG"
    ],
    "Summary Letter Date": "August 9, 2023",
    "Summary Letter Received Date": "May 26, 2023",
    "Submission Date": "August 01, 2023",
    "Regulation Number(s)": [
        "21 CFR 866.6010"
    ],
    "Regulation Name(s)": [
        "Tumor-Associated Antigen Immunological Test System"
    ],
    "Analyte Class(es)": [
        "immunology",
        "cancer molecular"
    ],
    "Analyte(s)": [
        "1116-NS-19-9 defined antigen (CA 19-9)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "EDTA tube",
        "Heparin tube"
    ],
    "Instrument(s)/Platform(s)": [
        "VITROS 5600 Integrated System"
    ],
    "Method(s)/Technology(ies)": [
        "Immunometric immunoassay",
        "Sandwich immunoassay",
        "Luminescent detection"
    ],
    "Methodologies": [
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent Pack",
        "Calibrator"
    ],
    "Document Summary": "FDA 510(k) summary for VITROS Immunodiagnostic Products CA 19-9TM Reagent Pack for quantitation of CA 19-9 in serum and plasma on the VITROS 5600 system",
    "Indications for Use Summary": "Quantitative measurement of CA 19-9 antigen in human serum and plasma (EDTA or heparin) to aid in management and monitoring of disease status in patients diagnosed with cancers of the exocrine pancreas using the VITROS 5600 Integrated System",
    "fda_folder": "Immunology"
}